The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients

Blood

Volumn 118, Issue 2, 2011, Pages 401-408

  Scherber, Robyn ^a   Dueck, Amylou C ^b   Johansson, Peter ^c   Barbui, Tiziano ^d   Barosi, Giovanni ^e   Vannucchi, Alessandro M ^f   Passamonti, Francesco ^g   Andreasson, Bjorn ^c   Ferarri, Maria L ^d   Rambaldi, Alessandro ^d   Samuelsson, Jan ^h   Birgegard, Gunnar ⁱ   Tefferi, Ayalew ^j   Harrison, Claire N ^k   Radia, Deepti ^k   Mesa, Ruben A ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b MAYO CLINIC   (United States)

^c NU Hospital Organization   (Sweden)

^d OSPEDALI RIUNITI   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h STOCKHOLM SÖDER HOSPITAL   (Sweden)

ⁱ UPPSALA UNIVERSITY   (Sweden)

^j MAYO CLINIC   (United States)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM; NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; THROMBOCYTHEMIA; VALIDATION STUDY;

EID: 79960437973     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-328955     Document Type: Article

References (23)

1. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. (Pubitemid 46120195)
2. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
3. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
4. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 Inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 313.
5. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
6. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438. (Pubitemid 351250553)
7. Mendoza TR. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186-1196. (Pubitemid 29115600)
8. Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8(2):94-104. (Pubitemid 40525371)
9. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. (Pubitemid 23073154)
10. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106(11):2397-2405. (Pubitemid 43787664)
11. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 Reference Values. Brussels, Belgium: EORTC Quality of Life Group Publications; 2008.
12. Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Haematologica. 2007;92(12):1596-1598.
13. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res. 2004;13(2):115-138. (Pubitemid 38379776)
14. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634-1646.
15. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24(9):1459-1473. (Pubitemid 46622014)
16. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of healthrelated quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18(4):775-781. (Pubitemid 46523284)
17. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma. 2005;46(12):1709-1714. (Pubitemid 43203103)
18. Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for firstline therapy: a study by the German CLL Study Group. J Clin Oncol. 2007;25(13):1722-1731. (Pubitemid 46797953)
19. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.
20. Scherber R, Mesa RA. Future therapies for the myeloproliferative neoplasms. Curr Hematol Malig Rep. 2011;6(1):22-27.
21. Pardanani AD, Gotlib JR, Jamieson CJ, et al. Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 459.
22. Verstovsek S, Deeg HJ, Odenike O, et al. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 3082.
23. Pardanani AD, George G, Lasho T, et al. A Phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 460.